You might like
📣We just published final results of our CHEERS trial @JAMAOnc investigating the combination of subtotal subablative SBRT ☢️ with anti-PD-(L)1 monotherapy 💉 in pts with advanced solid tumors ja.ma/3pBquxM
Absolutely, some more insight into overall disease burden is provided in the online supplements 🔎
Also, consider disease volume and velocity. If these are high, any therapy may have limited benefit. pubmed.ncbi.nlm.nih.gov/33599706/ If 7/45 pts had progression pre treatment, >2/3 were >1st line systemic tx, 50% had progression at 3 mos follow-up, it is likely a high risk cohort.
Words of wisdom on the NIVES trial: SBRT + nivo in mRCC. Our take on what is next and abandon the quest for the "abscopal" effect. @MathieuSpaas @NoraSundahl @_ShankarSiva @rweichselbaum bit.ly/3oOQXDq
Really pleased to bring this to fruition. Collaboration between multiple partners to shed insights on combination immunotherapy and radiotherapy, so as to guide best combination therapies! #RTimmuno #checkpoint blockade #precisionRT @ASTRO_org redjournal.org/article/S0360-…
Review: Characterisation & classification of #oligometastatic disease: a @ESTRO_RT and @EORTC consensus recommendation thelancet.com/journals/lanon…
Great news. Let's include as many as possible in the CHEERS trial when starting anti PD(L)-1. Maybe we can further improve the outcome! @JulesBordet #OncoAlert
#OncoAlert #ImmunoOnc Nivolumab treatment was associated with long-term survival in a subset of heavily pretreated patients with advanced melanoma, RCC, or NSCLC ja.ma/2TeMn10
United States Trends
- 1. Benfica N/A
- 2. Giannis N/A
- 3. Mourinho N/A
- 4. Nicki N/A
- 5. Apple cider vinegar N/A
- 6. #ChampionsLeague2026 N/A
- 7. Rashford N/A
- 8. Fulton County N/A
- 9. Arbeloa N/A
- 10. Joao Pedro N/A
- 11. Bucks N/A
- 12. Ms. Shirley N/A
- 13. Rand Paul N/A
- 14. Powell N/A
- 15. Rubio N/A
- 16. Barca N/A
- 17. #OlandriaxRobertWun N/A
- 18. Monken N/A
- 19. Bruce Springsteen N/A
- 20. Schwartz N/A
Something went wrong.
Something went wrong.